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Abstract  
Collagen VI myopathies are genetic disorders due to mutations in collagen 6 A1, 2, and 3 genes, 
ranging from the severe Ullrich congenital muscular dystrophy to the milder Bethlem Myopathy, 
which is recapitulated by collagen VI null (Col6a1-/-) mice. Abnormalities in mitochondria and 
autophagic pathway have been proposed as pathogenic causes of collagen VI myopathies, but the 
link between collagen VI defects and these metabolic circuits remains unknown. To unravel the 
expression profiling perturbation in muscles with collagen VI myopathies we performed a deep 
RNA profiling in both Col6a1-/- mice and ColVI patients. Interactome map identified common 
pathways suggesting a previously undetected connection between circadian genes and collagen 
VI pathology. Intriguingly, Bmal1-/- mice, a well-characterized model displaying arrhythmic cir-
cadian rhythms, showed profound deregulation of the collagen VI pathway and autophagy-
related genes.  
The involvement of circadian rhythms in collagen VI myopathies is new and links autophagy 
and mitochondrial abnormalities. It also opens new avenues for therapies of hereditary myopa-
thies to modulate the molecular clock or potential gene-environment interactions that may modi-
fy muscle damage pathogenesis.  
  
  
Introduction 
Collagen VI (ColVI) is a major component of the extracellular matrix (ECM) crucial for muscle 
cell adhesion, stability and regeneration. COLVI forms a microfibrillar network involved in 
maintaining tissue integrity through a structural link between different components of connec-
tive-tissue basement membranes and cells (Allamand et al., 2011). COLVI is a heterotrimeric 
molecule composed of three -chains encoded by distinct genes (COL6A1, COL6A2, COL6A3). 
Equimolar association of the three alpha−chains into a triple helical monomer is followed by 
formation of dimers and tetramers stabilized by disulfide bonds. After secretion, the tetramers 
form a network of microfilaments that bridge the surface of muscle cells with the connective tis-
sue (Bonaldo et al., 1990). Mutations occurring in the three ColVI genes cause two major disease 
phenotypes: a mild form, Bethlem myopathy (BM), and a severe form, Ullrich congenital mus-
cular dystrophy (UCMD) (Gualandi et al., 2012). Three additional ColVI genes have recently 
been described, COL6A4, COL6A5 and COL6A6, and code for the 4(VI), 5(VI) and 6(VI) 
protein chains, respectively. However, only 6(VI) is highly expressed in skeletal muscle, alt-
hough not associated with basement membranes (Tagliavini et al., 2014a) and none of these ad-
ditional ColVI genes are known as disease genes in humans. 
COLVI myopathies are well defined conditions, characterized by a broad spectrum of clinical 
features, ranging from prenatal onset with decreased fetal movements; hypotonia or torticollis, 
early-childhood onset - by delayed motor milestones, muscle weakness and contractures; and 
adult onset (4th-6th decade) - by proximal weakness and Achilles tendon or long finger flexor 
contractures (De Visser et al., 2004). As a result of slow but ongoing progression of the condi-
tion, more than two-thirds of affected individuals over age 50 years need supportive means for 
outdoor mobility (Jöbsis et al., 1999). 
The severe phenotype with early onset, UCMD, is characterized by severe muscle weakness, 
striking hyperlaxity of distal joints, and proximal joint contractures. In contrast to BM, UCMD is 
marked by an early loss of ambulation and a rapid disease progression leading to early death 
caused by respiratory failure (Maraldi et al., 2009). In addition, two other conditions have been 
associated with COLVI myopathy: autosomal dominant limb-girdle muscular dystrophy 
(LGMD), and autosomal recessive myosclerosis myopathy (Merlini et al., 2008; Scacheri et al., 
2002). Recently, the COL12A1 gene was shown to be mutated in patients with a BM-like pheno-
type (Hicks et al., 2014). 
Despite this broad clinical spectrum, both muscle function and respiratory performance evalua-
tion can address the diagnosis. Nevertheless, UCMD and BM can be inherited accordingly to 
both dominant and recessive models, and generally, neither the type of mutation (missense, non-
sense, splicing insertion or deletion), nor the effect of the mutation on the protein struc-
  
ture/function allows precise discrimination between two phenotypes (Allamand et al., 2011; 
Maraldi et al., 2009; Bönnemann, 2011). This suggests that the genetic background of patients 
may influence the mutated genes expression, therefore impacting on the resulting phenotype. 
The Col6a1-/- mouse is a well characterized animal model for COLVI myopathies. These mice 
carry a targeted inactivation of the 1(VI) chain and exhibit an early onset myopathic phenotype 
that strongly resembles BM (Bonaldo et al., 1998). Muscle fibres of Col6a1-/- mice show loss of 
contractile strength and a number of structural defects in the hind limb muscle and especially in 
the diaphragm. Although the pathology associated with collagen VI myopathy is nonspecific and 
variable, it has been widely documented (Grumati et al., 2010; Urciolo et al., 2013). Defective 
mitochondrial function with ultrastructural alterations, increased spontaneous apoptosis and ab-
normal propensity of the permeability transition pore (PTP) to open, have been characterized in 
both animal models and patients (Irwin et al. 2003; Bernardi and Bonaldo, 2008; Tagliavini et 
al., 2014b). 
A further link between COLVI myopathies and mitochondrial dysfunction has been established 
by the discovery that autophagy is defective in Col6a1-/- mice and UCMD/BM patients (Grumati 
et al., 2011). This supports a mechanism of disease pathogenesis that might be in part due to de-
fective regulation of autophagy, which leads to accumulation of abnormal mitochondria and sar-
coplasmic reticulum. Moreover, in Col6a1-/- mice, changes in metabolic proteins resulting in de-
creased glycolysis and affecting the tricarboxylic acid (TCA) cycle fluxes lead to a different fate 
of a-ketoglutarate triggering lipotoxicity. The metabolic changes are associated with changes of 
proteins involved in mechanotransduction at the myotendineous junction/costameric/sarcomeric 
level and in energy metabolism (De Palma et al., 2013). Recently, a strong depletion of the 
6(VI) chain in skeletal muscle has been reported as potential biomarker of COLVI myopathies 
(Tagliavini et al., 2014a). In spite of these recent achievements, a complete understanding of 
COLVI disease pathogenesis remains elusive. 
Gene expression profiling and RNA sequencing are powerful tools for exploring the alterations 
of transcriptional behavior in disease tissues (Sánchez-Pla et al., 2012). It brought great advances 
in cancer research and disclosed deregulated transcripts that are now being considered as prog-
nostic/therapeutic biomarkers of neoplastic diseases (Sevov et al., 2012; Campo, 2013). Consid-
ering the availability of novel therapeutic possibilities for rare muscle disorders (Aartsma-Rus 
and Muntoni, 2013), finding prognostic biomarkers for disease severity or drug response will be 
of great benefit for patient care and treatment (Ferlini et al., 2013; Scotton et al., 2014). In this 
work, we explored RNA profiling of Col6a1-/- mice and BM/UCMD patients to identify tran-
scriptional patterns correlating with disease state. Such patterns can identify specific pathway al-
terations and pathophysiological biomarkers. This unbiased approach revealed marked changes 
  
in the expression of genes involved in the circadian rhythm pathway. We further supported these 
findings by protein studies performed both in mice and in patients. In addition, RNA and protein 
studies in the Bmal1-/- mice, a known animal model of circadian rhythm disruption, showed pro-
found deregulation of Col6a6 as well as of the autophagy-related genes such as p62/SQSTM1 
and AMPK. Although it has been previously reported that disruption of circadian rhythms are 
linked to skeletal muscle remodeling, function, performance and aging, the involvement of the 
molecular clock genes in hereditary myopathy as COLVI disease is a novel finding. These find-
ings open new perspectives on potential target genes involved in muscle damage pathogenesis 
and offers new therapeutic approaches. 
 
Results 
Overall gene expression profile in Col6a1-/- muscles reveals changes in genes associated 
with muscle function 
Gene expression array profiles of wild-type (WT) and Col6a1-/- mice were compared in three 
muscle types: diaphragm, tibialis anterior (TA) and gastrocnemius. To determine genes with sta-
tistically significant differential expression (p-value < 0.05 in limma package) we analysed each 
muscle type both separately and in pools (averaged expression change over all muscle types). 
The degree of transcriptional deregulation was different among Col6a1-/- muscles with 11,170 
differentially expressed genes in TA, 6,790 in diaphragm and 3,759 genes in gastrocnemius. To 
further support the finding of different tissue susceptibility to COLVI deficiency, we performed 
sample clustering of expression profiles from each muscle type in both Col6a1-/- and WT mice. 
The resulting dendrogram is shown in supplementary figure 1A. We found that expression pro-
files of Col6a1-/- and WT gastrocnemius were clustered together and therefore similar. Indeed 
this supports the existing knowledge about muscle involvement in the Col6a1-/- mouse model, 
where gastrocnemius is very mildly affected, whereas tibialis and even more diaphragm are se-
verely affected (De Palma et al., 2013). In contrast, diaphragm and TA Col6a1-/- muscles clus-
tered together and clearly separate from their WT counterparts, suggesting that COLVI deficien-
cy severely and similarly affects these muscle types (Fig. S1). 
Expression of genes associated with muscle development and function was altered in Col6a1-/- 
mice (supplementary table 1). The changes affected multiple aspects of muscle biology including 
structure, metabolism, transcription and regulation. There was variability between tested muscle 
types. 60% (26 out of 44) of muscle-specific genes changed their expression in an opposite di-
rection in TA versus diaphragm, 23% in TA versus gastrocnemius (7 out of 30) and 67% in gas-
trocnemius versus diaphragm (12 of 18). TA displayed differential expression of myosin, tro-
ponin and calsequestrin isoforms (predominantly cardiac and slow), and increased expression of 
  
Pax3. Genes differentially expressed in diaphragm and TA included almost all members of the 
dystroglycan complex (dystrophin, dystrobrevin, dystroglycan 1, syntrophin, -, -, -
sarcoglycans) and several transcription factors important for muscle-related processes, such as 
MyoD1, MyoG, MYF6, NFATc2 and Pax7. In the diaphragm, embryonic isoforms of myosin 
were upregulated as well as Pax7, a marker of satellite cell number, which together can be re-
garded as a sign of muscle regeneration. These muscle type variability in the transcription profile 
is not surprising since these three muscles have different metabolic properties and different fiber 
type composition (Bonaldo et al., 1998). 
 
Gene ontology groups and key expression regulators analyses show deregulation of the cir-
cadian rhythmic process in Col6a1-/- mice 
Among differentially expressed genes between Col6a1-/- and WT mice, 479 changed expression 
in the same direction in all tissues with p-value < 0.05. We used Gene Set Enrichment analysis 
(GSEA) to identify gene ontology (GO) groups enriched with such genes. The top 10 GO groups 
are listed in Supplementary figure 2. Identified GO groups were broad categories not specific 
enough to yield an insight regarding the biological effects occurring in Col6a1-/- mice. We also 
performed GO analysis of 334 genes differentially expressed in the "pooled" data from all three 
muscle groups compared with “pooled” WT muscles. This GSEA identified the GO groups 
shown in Figure 1. One of the top 10 GO groups was "rhythmic process" containing genes regu-
lating circadian rhythms as well as known genes that are regulated downstream of the molecular 
clock, such as DBP, and all were down-regulated in Col6a1-/- muscles. 
To identify key regulators that change their activity in Col6a1-/- muscles, we used sub-network 
enrichment analysis (SNEA) in Pathway Studio. Our first SNEA was done using the list of genes 
differentially expressed in one direction in all muscle types as an input. Regulators identified by 
this approach are shown in Figure 2. Genes changing their expression in one direction in all 
muscle types are primarily regulated by inflammatory cytokines and their receptors. In good 
agreement with the GO analysis, SNEA of the "pooled" dataset found ARNTL (gene encoding 
the molecular clock factor, BMAL1), CLOCK, PER1, and PER3 regulators that belong to cellu-
lar circadian rhythm pathway (Fig. 2 and table S2).  We then explored the intersection between 
the two SNEA analyses and found consistent results (Fig. 2 and table S2). Indeed, we found 
CLOCK, ARNTL, GFI1B, IL2, CD28, PIM3 and inflammatory cytokines key regulators up-
stream of genes differentially expressed in all comparisons. In total 46 key regulators were iden-
tified by the three comparisons. 
To validate the 46 key regulators selected by SNEA, we explored the differential expression of 
these transcripts using TaqMan low-density arrays (TLDA). Comparison of the data obtained 
  
from both the microarray experiments and those with the TLDA cards resulted in the same trend 
of fold change in 37 out of 46 genes (80%) of the diaphragm and TA, whereas in the gas-
trocnemius we found 32 out of 46 genes (70%) with these characteristics (Figs. S3A, S3B).  
The TLDA and microarray data for regulators of the rhythmic process (ARNTL, ATF5, 
CLOCK, DBP, EGR1, FKBP5, PER1, PER2 and PER3) and transcription factors important for 
muscle-related processes (MYOD, MYOG, MYF6, PAX7) were in good agreement in both dia-
phragm and TA and to a lesser extent in gastrocnemius, confirming the deregulation of these two 
pathways in the Col6a1-/- mice (Fig. S3B).   
Western blot revealed that CLOCK levels were significantly (Student’s t-test, n = 3, p-value < 
0.05) increased in diaphragm and TA muscles of Col6a1-/- mice compared with their respective 
WT controls, whereas they remained unchanged in gastrocnemius. MAT2A protein levels did 
not change significantly in the diaphragm, whereas in TA and gastrocnemius muscles they were, 
respectively, increased and decreased (Fig. 3A). 
 
Abnormal collagen VI expression in Bmal1-/- mice, a model for circadian rhythm deregula-
tion  
There are multiple genetic mouse models in which molecular clock factors have been knocked 
out, but of these models only the Bmal1-/- mice exhibit complete loss of behavioral rhythm under 
normal housing conditions (Bunger et al., 2000). We adopted this last model in order to have a 
homogeneous phenotype, with complete failure of circadian control.  Western blot analysis of 
gastrocnemius muscles of Bmal1-/- mice revealed significant changes in the levels of COLVI 
chains, with decreased 6(VI) and increased 3(VI) levels. Interestingly, down-regulation of 
COL6A6 was also recently observed by us in UCMD and BM muscles (4). In addition to 
COLVI, components of the autophagy pathway were also affected in the muscle of Bmal1-/- mice 
with increased LC3 and decreased p62/SQSTM1 levels, whereas Beclin 1 levels were un-
changed. We also found increase in the activation status of AMPK, as defined by higher 
phospho-AMPK/total AMPK, however this was driven in part by a significant decrease in the 
levels of total AMPK (Fig. 3B).  
 
Circadian genes show deregulation in muscle from UCMD and BM patients. 
Gene expression profiles in the 3 patients (1 UCMD and 2 BM) compared to healthy controls by 
RNAseq identified several altered transcripts grouped into GO categories (Fig.4A). Consistently 
deregulated genes in muscles from UCMD/BM patients are reported in Table 1. In all three pa-
tients, we identified 7 consistently upregulated genes belonging to transcription factor, metabo-
lism process and cellular stress response categories. The 24 consistently downregulated genes 
  
are involved in signaling, metabolism, immunity and cell adhesion, axon guidance and circadian 
rhythm including DNA repair GO categories (Fig. 4B). Consistent with a link to circadian 
rhythms we found that 8 of the genes listed in Table 1 are known to be circadian in mouse skele-
tal muscle and/or changed in expression in the Bmal1-/- mouse.  
In order to find GO groups deregulated in different samples, we performed GSEA analysis (p-
value 0.05 cut-off) for each patient separately. The bi-clustering was performed using Jaccard-
based distance between GO groups (based on the number of common genes in groups). This 
method allowed finding common deregulated “patterns” in different patients, even though the 
GSEA method shows different GO groups. We found genes coding for postsynaptic mem-
brane/cell junction/synapse, regulation of ion transmembrane transport, protein homo-
oligomerization/protein specific binding, cell surface receptor linked signalling pathway and 
DNA repair/response to DNA damage, including circadian rhythm genes (Figs. 4A, 4B). 
Considering the evidence from both mice and human studies for the deregulation of circadian 
genes in muscles with COLVI defects, we performed expression analysis by real time PCR of 
CLOCK and MAT2A genes in other 11 UCMD and 12 BM patients. We found that CLOCK 
gene was significantly downregulated (p value < 0.0001) in all UCMD muscles. The MAT2A 
transcript showed a milder downregulation, albeit not statistically significant (p value: 0.0753), 
only in UCMD patients (Fig. 3C). BM patients do not show any significant deregulation in the 
analysed circadian genes. Western blot in 4 UCMD and 3 BM patient muscles showed signifi-
cantly increased CLOCK protein levels (ANOVA + Tukey, n = 3, p-value < 0.05) in UCMD pa-
tients only, whereas MAT2A protein levels were increased in BM patients only (Fig. 3D). 
 
Discussion 
ColVI myopathies have been both clinically and genetically defined, and alterations in the apop-
tosis and autophagy circuits have been reported. Nevertheless, the link between mutations of 
COL6A1-COL6A3 genes and the muscle dysfunction seen in ColVI myopathy still remains elu-
sive. We therefore adopted RNA profiling to study muscle from both Col6a1-/- mice and 
BM/UCMD patient biopsies, searching for unique transcriptional patterns. The idea was to detect 
specific signatures that may enhance our understanding of the pathogenesis of ColVI myopa-
thies. In order to strengthen our findings, we also evaluated protein expression of the transcripts 
that we found to be consistently deregulated in both mouse and patient muscle tissue. 
 
Col6a1-/- and Bmal1-/- mice shows connection between ColVI myopathy and circadian genes 
To our knowledge this is the first attempt to study Col6a1-/- mice by RNA profiling. Proteomic 
studies were performed by Irwin et al. (Irwin et al., 2003) in Col6a1-/- mice, revealing the dia-
  
phragm as the most severely affected muscle, having a deeply subverted ultrastructure and evi-
dent loss of contractile strength, accompanied by changes in proteins involved in 
mechanotransduction. Our pooled data identified 334 differentially expressed genes in Col6a1-/- 
versus WT, showing consistent deregulation of the genes involved in metabolic processes and 
regulation of transcription, known to be affected in myopathies, as well as of the circadian 
CLOCK gene. This is an entirely new observation. 
We show major transcriptional changes in the diaphragm and TA, accordingly to the proteomic 
findings (De Palma et al., 2013). All muscles shared similar alterations in the genes involved in 
the inflammatory response, cell proliferation, transcriptional regulation, and metabolism, but dif-
fered substantially in the sign of expression of a number of genes associated with muscle func-
tions, including structure, metabolism, transcription, and regulation – a not entirely unexpected 
finding considering that these three muscles have different morphogenetic origins and functional 
requirements (Eberhard and Jockusch, 2004; Merrell and Kardon, 2013). 
The CLOCK gene deregulation, we also confirmed at the protein level in Col6a1-/- mice, sug-
gests a previously unreported relationship between circadian rhythms, the molecular clock and 
myopathy. Col6a1-/- model shows both muscle and osteotendinous junction damage (Izu et al., 
2011; Izu et al., 2012), reflecting defective costamerogenesis and altered mechanotransduction 
(De Palma et al., 2013). Specific activation of either MRTFs (myocardin-related transcription 
factors) and TCFs (ternary complex factors), whose targets are regulators of cytoskeleton dy-
namics and mechanosensing, have potential to reset the molecular clock via regulation of PER1, 
PER2, ARNTL and other CLOCK genes (Esnault et al., 2014). This first link between the ECM 
and the profound alterations we detected in the circadian rhythm/molecular clock pathway 
(ARNTL, ATF5, CLOCK, DBP, EGR1, FKBP5, PER1, PER2 and PER3 genes) supports the 
known data demonstrating that physical activity/exercise can regulate circadian gene expression 
in skeletal muscle (Wolff and Esser, 2012). In addition, providing a further bridge between pro-
tein and RNA data, intersection between the individual muscle groups and the pooled transcrip-
tion data, to identify key regulators, showed that inflammatory cytokines and their receptors, 
known to be regulated by PER1-3 genes, are significantly under-expressed. The connection be-
tween ColVI and circadian genes is also strongly supported by our protein findings in Bmal1-/- 
mice, which exhibit significant changes in the levels of COLVI chains as well as alterations of 
the autophagy pathway (Fig.3B). Since our expression analyses were only performed at one time 
point, our results can only allow us to conclude that molecular clock pathway is disrupted. Fur-
ther studies are needed to determine whether the clock factors are phase shifted, damped or ar-
rhythmic. 
 
  
RNA profiling of COLVI patients shows profound deregulation in ECM-mediated struc-
tural muscle remodeling and circadian genes 
In the 3 ColVI patients (BM, BMs and UCMD) studied, the highly efficient RNAseq analysis 
revealed many changes in transcription profile, as expected for this progressive, chronic and se-
vere myopathy. The major changes observed, shared by all patients, were under- or overexpres-
sion in membrane/cell junction/synapse, ion transmembrane transport, protein homo-
oligomerization/protein-specific binding, cell-surface-receptor-linked signaling pathway and cir-
cadian gene pathways (Fig. 4B). The overexpressed genes we detected (ZNF384, ZNF526, 
SCP2, SUOX, KIF1B, PCSK6 and SESN1) are all involved in the control of gene expression 
and metabolic pathways. As reported in UCMD muscles (Paco et al., 2013), increased expres-
sion of these transcripts is associated with muscle regeneration defects and inflammatory signa-
tures. Our RNAseq data confirm that this myopathy is associated with structural alterations cou-
pled with either signaling or regeneration failure (Bönnemann, 2011). The 24 down-regulated 
genes we identified mainly involved transcripts associated with cell-cell communica-
tion/adhesion and signaling. Deregulation of transcription, homeostasis, and cell response was 
also evident. This RNAseq data combines with that obtained by Paco et al. (Paco et al., 2013) us-
ing array technology to indicate that COLVI deficiency drives both structural remodeling of 
muscle tissue, mediated by ECM, adhesion, cell-signaling and metabolism genes, and a massive 
immune response. The central role of metabolism in muscle remodeling has also been confirmed 
by De Palma et al. (De Palma et al., 2014), who described changes in the unfolded protein re-
sponse coupled with metabolic dysregulation, autophagic impairment, and mechanotransduction 
signaling alterations.  
Most intriguingly, and in line with the mouse data, our RNAseq analysis also revealed that cir-
cadian-related CRY2 and MAT2A genes were profoundly deregulated. CRY2 is a well-
established negative regulator of the molecular clock mechanism that underlies circadian 
rhythms, and MAT2A has a link with circadian rhythms through regulation of the enzyme re-
quired for melatonin synthesis, and mediates photoneural-circadian regulation of the pineal gland 
(Kim et al., 2005). Using array technology, Paco et al. (Paco et al., 2013) also identified signifi-
cant deregulation of the CLOCK pathway gene EGR1, which also supports circadian rhythm in-
volvement in the pathogenesis of COLVI in both mice and patients. This finding prompted us to 
profile both MAT2A and CLOCK in a larger patient cohorts, and the CLOCK gene was signifi-
cantly downregulated (p value < 0.0001) in all UCMD, the more severe form of ColVI myopa-
thy. All these data support that circadian genes and CLOCK in particular, have a role in ColVI 
myopathy pathogenesis. 
 
  
Circadian genes and hereditary myopathies: a new perspective  
Circadian rhythms are approximate 24hr oscillations in physiology and behavior driven by the 
molecular clock, a transcription-translation feedback mechanism. A link between circadian genes 
and skeletal muscle has been identified in both animal models and in humans (Schroder and 
Esser, 2013). In particular, expression profiling has identified genes expressed in a circadian 
manner in the gastrocnemius, soleus and TA muscles of mice (McCarthy et al., 2007; Dyar et al., 
2013; Hodge et al., 2015). Analysis of human muscle samples taken 12 hours apart have also 
shown changes in clock-gene expression, consistent with the findings in mice (Zambon et al., 
2003). Indeed, Zhang et al. (Zhang et al., 2012) found that the molecular clock factors 
BMAL1:CLOCK transcriptionally regulate expression of MyoD1 in adult muscle, thereby sug-
gesting a link between the daily clock cycle and periods of muscle repair and maintenance. We 
add to this growing body of evidence by demonstrating, by RNA and protein analysis, a novel 
link between COLVI myopathy and deregulation of CLOCK circadian gene expression in both 
mouse and human tissues. 
In mice, the protein data fully support the transcription results. Altered expression of CLOCK 
seems to be a marker of COLVI disease severity, being upregulated in the most profoundly af-
fected muscles (TA and diaphragm). In this way, CLOCK involvement appears to provide the 
missing link between autophagic pathway alterations and the physiopathogenesis of COLVI my-
opathies (Fig. 5). Supporting this link, many mitochondrial genes show a circadian oscillation in 
expression and are significantly downregulated in the muscle of Clock mutant mice (McCarthy 
et al., 2007); in addition, the circadian animal models (both Clock 19 and Bmal1-/-) have a dra-
matic reduction (40% less) in the mitochondrial volume. In these mutant mice the remaining mi-
tochondria display a pathological morphology characterized by swelling and disruption of cris-
tae, associated with an increased uncoupling of respiration (Andrews et al., 2010). These find-
ings suggest that circadian genes can modulate the respiratory defects. Unsurprisingly, therefore, 
protein analysis in the Bmal1-/- mice identified a reduced expression of the 6(VI) chain. Inter-
estingly, a severe depletion of the 6(VI) chain has recently been identified both in skeletal mus-
cle and muscle cell cultures of COLVI patients, and this protein change has been proposed as a 
diagnostic marker of COLVI diseases (Tagliavini et al., 2014a). Indeed, timing plays a crucial 
role in muscle remodeling. For instance, Dadgar et al., (Dadgar et al., 2014) demonstrated that 
asynchrony drives fibrosis and regeneration failure in the mdx model, finding a link between 
profound deregulation of global muscle transcription and the muscle damage seen in various 
dystrophies, including dystrophinopathies and several LGMD types.  
Recently, BMAL1 was found to be involved in myogenic response to muscle damage, orches-
trating the regeneration processes in adult skeletal muscle (Chatterjee et al., 2015) 
  
Although these studies suggest that circadian circuit plays a critical role in muscle function and 
regeneration, the mechanism mediating these effects in skeletal muscle-wasting diseases remains 
to be elucidated. 
Our results demonstrate, for the first time, a deregulation of circadian genes in skeletal muscle of 
COLVI myopathy  that may lead to characterizing the involvement of circadian clock in many 
other muscle-wasting diseases, opening new therapeutical perspectives.  
Putative models linking collagen VI myopathies with circadian rhythm deregulation  
The new data suggest a pathogenic connection between circadian-rhythm-gene deregulation and 
collagen-VI-related myopathies. It appears that CLOCK gene deregulation could provide a link 
between autophagy, mitochondrial abnormalities, and COLVI diseases. In light of the asyn-
chrony recently described as the mechanism driving regeneration failure (Dadgar et al., 2014), 
this relationship could be expressed as one of the two following scenarios: 
1) Circadian rhythm deregulation is a downstream effect of COLVI deficiency and contributes 
to muscle damage pathogenesis (Fig. 6A). In this hypothesis, the critical player interconnecting 
COLVI deficiency with circadian rhythm could be the inappropriate persistence of AKT1 activa-
tion. Due to the reduced COLVI expression, this would lead not only to the down-regulation of 
autophagy (Grumati and Bonaldo, 2012), but also to the activation of HIF1A transcription factor 
and the consequent downregulation of GSK3-beta kinase. Indeed, muscle regeneration is a finely 
regulated process which drives the transcription of myogenic factors through the orchestration of 
cell contact, growth factors and various hormones. Murine models lacking or constitutively ex-
pressing AKT genes show severe muscle deficiency or extensive hypertrophy, respectively (Wil-
son and Rotwein, 2007; Peng et al., 2003, Lai et al., 2004), implicating AKT genes (1 and 2) in 
both the development and regeneration of muscle. Serra et al. (Serra et al., 2007) hypothesize 
that this may arise through convergence of the AKT pathway and the p38 circuit at the chromatin 
level controlling the assembly of myogenic transcriptome and driving the regeneration process. 
2) Circadian rhythm deregulation in COLVI myopathies is an independent event acting as a 
secondary modifier of disease severity (Fig. 6B). Our observation that the collagen VI 6 chain 
is downregulated in a mouse circadian model could suggest that circadian genes are genetic 
modifiers able to influence the primary COLVI defect. It is well recognized that the molecular 
clock in skeletal muscle can be modified by environmental factors including time of feeding or 
time of physical activity (Wolff and Esser, 2012; Hatori and Panda, 2015).  Merging this concept 
with the known direct control that circadian genes have on MyoD (muscle development), PGC1 
(mitochondria) and ATG14 (autophagy circuit) proteins provides the model through which cir-
cadian rhythm disruption could function independently to modify disease severity. It may there-
fore be enlightening to explore circadian genes in the many COLVI patients whose causative 
  
mutations are still unknown (recently mutations in COL12A1 gene have been linked to the 
UCMD/BM phenotype) (Hicks et al., 2014). 
In conclusion, our demonstration of circadian gene involvement in the pathogenesis of COLVI 
myopathy in both an animal model and human patients opens novel avenues for both pathogene-
sis and treatment of hereditary muscle diseases. Timing and synchronization may have different 
effects on gene expression, depending on the specific gene mutation (COL6 or DMD). Different 
key regulators, such as AKT1 for COL6 myopathies and TGFB1 for dystrophin mutations 
(Dadgar et al., 2014), may be implicated, as these two muscle diseases have different pathogenic 
signatures, represented by defective autophagy and massive muscle necrosis, respectively. Final-
ly, since CLOCK is downregulated only in the severe UCMD phenotype, it should be further ex-
plored as a severity biomarker in patients with myopathies characterized by a severe muscle re-
modeling, with a view to applications in both disease stratification in patients and monitoring in 
clinical trials. 
 
Material and Methods 
Analysis of Col6a1-/- mice 
RNA extraction 
For the focus of this work, we used standardized timing of muscle tissue collection from the 
Col6a1-/- mice and the Bmal1-/- mice. Mice in all colonies were maintained in normal 12L/12D 
schedules with lights on at 7am (Zeitgeber time - ZT0). Muscle tissues were collected between 
10am to 12pm (ZT3-5) and frozen immediately in liquid N2. By following these strict time of 
collection procedures this allows comparisons across tissues and between animals. Both WT and 
Col6a1-/- mice belong to C57BL/6 strain regarding the fiber type composition of different mus-
cles as previously described (Augusto et al., 2004 )  
 
Total RNA was isolated from three muscles (diaphragm, gastrocnemius and tibialis) of four male 
mice for each condition (wild type and knock out, aging 6 months) using the TRIzol extraction 
(Invitrogen) as specified by the manufacturer. RNA from each muscle was quantified with 
Nanodrop (Thermo scientific) spectrophotometer. Its integrity was evaluated with a 2100 
Bioanalyser (Agilent) prior to pooling equal amounts of RNA from muscles of the same kind. 
 
Whole genome expression microarray analysis 
We used the Whole Mouse Genome gene expression kit composed by four arrays of 44,000 
probes (Agilent Technologies, G4122F) to measure transcriptional profile of muscle tissue sam-
ples of four mice. Sample labelling and hybridization were performed in triplicates according to 
  
protocols provided by Agilent (One-Colour Microarray-Based Gene Expression Analysis version 
5.0.1). The hybridized array was processed by Agilent scanner and Feature Extraction software 
(v9.5). Uniformness of array hybridization was verified via Agilent Quality Controls (Spike-in), 
consisting of a mixture of 10 in vitro-synthesized, polyadenylated transcripts derived from the 
Adenovirus E1A gene, premixed at concentrations spanning six logs and differing by one-log or 
half-log increments. 
 
Microarray data analysis  
Agilent's Feature Extraction Software (v9.5) was used for array image processing. Intensity data 
with local background adjustment by spatial detrending were log-transformed and quantile-
normalized. Synonymous probes from the same gene were averaged. Software selected 28,052 
probes for further analysis. To perform multi-way comparisons we utilized limma package 
(Smyth et al., 2005). This package fits a separate linear model for each gene and uses moderated 
t-statistics to estimate differences between arrays. Empirical Bayes analysis is used to improve 
statistical power in small sample sizes. P-values were corrected for multiple testing using the 
Benjamini & Hochberg correction (Benjamini and Hochberg, 1995). 
To ascribe biological changes in KO vs. WT muscles we used Gene Ontology term enrichment 
analysis. GO terms enriched with differentially expressed genes were identified using Fisher ex-
act test. We also performed Gene Set Enrichment analysis (GSEA), (Subramanian et al., 2005) 
using Pathway Studio 9 from Elsevier. 
Potential transcription regulators of the observed expression changes were identified using sub-
network enrichment analysis (Sivachenko et al., 2007) with default parameters implemented in 
Pathway Studio. This algorithm identifies sub-networks consisting of a single expression regula-
tor (for example, transcription factor) and its downstream genes showing concordant changes in 
expression between two conditions. Information about gene-gene regulations is extracted from 
the literature using natural language processing and stored in Pathway Studio database. At the 
time of analysis, the database contained over 250,000 Expression relations between proteins. Re-
lations were extracted by natural language processing of more than 22 million PubMed abstracts 
and 880,000 full-text articles. 
 
Microarray data analysis validation by fluidic cards (TLDA) 
46 genes were selected for fluidic card analysis based on both differential expression between 
wild type and KO mice and literature analysis in Pathway Studio to find genes associated with 
circadian rhythm pathway, muscle regeneration, autophagy, and apoptosis. Selected genes were 
used to set up a custom TaqMan low density array (TLDA or Fluidic card) according to manu-
  
facturer specifications in order to validate results obtained using the microarray platform. MIP 
gene (major intrinsic protein of lens fiber) was selected as negative control for its absence of ex-
pression in the microarray data. Single fluidic card can analyse 48 genes (47 test and the 18S 
control housekeeping gene) simultaneously in eight samples and was run five times for each 
sample, it also included major autophagic effector protein beclin-1 (Grumati et al., 2010). 
150 ng for each RNA pool was retrotranscribed using High-Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems), according to manufacturer's instructions and loaded in a single 
port of the TLDA run on ABI 7900HT System (Applied biosystem) for 2 min at 50 °C, 10 min at 
95 °C, followed by 40 cycles for 15 s at 97 °C and 1 min at 60 °C.  Data analysis was performed 
following the CT Method (Applied Biosystems User Bulletin #2) and using the 18S gene as 
calibrator and the WT samples as controls with respect to the KO samples. Calculated mean 2-
CT has been Log transformed and compared with normalized fold change microarray data. 
 
Western blotting and RNA analysis in Bmal1-/- mice 
Immunoblotting was used to evaluate protein levels of LC3/MAP1LC3A (Rabbit polyclonal, 
Thermo scientific, PA1-16930, 1:1000), BECLIN1 (D40C5 Rabbit mAb, Cell SignalingTech, 
3495, 1:1000), P62/SQSTM1 (Guinea pig polyclonal, Progen GP62-C, 1:1000), AMPK (Rabbit 
polyclonal, Cell SignalingTech, 2532, 1:1000), p-AMPK (Rabbit polyclonal, Cell 
SignallingTech, 2531, 1:1000), COL6A1 (COL6A1 H-200, Santa Cruz Biotech, sc-20649, 
1:1000), COL6A3 and COL6A6 (rabbit polyclonal antisera against mouse a3(VI) and a6(VI) 
were kindly 
supplied by R. Wagener, Colonie, Germany). Gastrocnemius muscles from 30-35 week old male 
wild type (n=4) and Bmal1-/- (Andrews et al., 2010; Bunger et al., 2000) mice (n-4) were ho-
mogenized using extraction buffer (2% SDS, 10% glycerol, 2% 2-mercaptoethanol, 50mM Tris-
HCl, pH8.8). The homogenized samples were immediately incubated at 80°C for 5 min and pro-
tein concentration was measured using BioRad DC protein assay kit. The protein samples 
(50µg/lane) were then subjected to 7.5% (for ColVI) or 10% SDS-PAGE. After electrophoresis, 
proteins were transferred to PVDF membrane (Millipore). The membrane was blocked in Odys-
sey blocking buffer (LI-COR) for 1 hour and then incubated with primary Ab in 50% Odyssey 
blocking buffer (LI-COR) diluted with 1 X PBS containing 0.1% Tween for 1 hour. The mem-
brane was then washed and incubated with HRP-conjugated secondary Ab (for all Collagen VI 
proteins and p62) or Alexa Fluor 680 secondary Ab diluted in in 50% Odyssey blocking buffer 
(LI-COR). The protein signal was detected either by incubation with ECL substrate and signals 
was developed by exposing the membrane to CL-Xposure film (for HRP-conjugated secondary 
Ab), or by using the Odyssey infrared imager (LI-COR, for Alexa Fluor 680 Ab). The protein 
  
bands were analyzed by using Image J. The plots in the figures are average of four samples for 
both wild type and Bmal1-/-. * indicates p<0.05. 
All animal procedures were conducted in accordance with institutional guidelines for the care 
and use of laboratory animals as approved by the AAALAC accredited, University of Kentucky 
Institutional Animal Care and Use Committees with the protocol number: 00728M2004. 
 
Analysis of BM/UCMD patients 
RNA extraction 
The three ColVI patients have the following mutations  
- UCMD patient: heterozygous c.819_833del p.Pro274_Gly278del in COL6A1 gene  
- severe BM patient: homozygous c.1393C>T p.Arg465* in COL6A3 gene 
- BM patient: heterozygous c.428+1G>A p. Tyr122_Gly143del in COL6A1 gene 
We obtained muscle biopsies from ColVI patients after informed consent and approval of the 
Ethics Committee of the University of Ferrara (N. 02/2009, 26th of February 2009).  
Muscle biopsy procedures were taken at a time according to the local clinics rules, ranging from 
8-10 am (central Europe time) or 10-12 am (Greenwich time), depending on the sites. Fresh bi-
opsies were frozen following routine procedures. Because of the similarity in time of collection, 
comparison of molecular clock components across patient samples can be made. The muscle fi-
ber composition in these three muscles shows a predominance of fiber type I (Fig. S4).  
Generally, hereditary myopathies, including the collagen VI myopathies, are characterized by the 
fiber type disproportion with type I fiber hypotrophy and predominance. (Schessl et al. 2008).  
Total RNA was isolated from skeletal muscle biopsies of three patients with different pheno-
types: UCMD, dominant and recessive BM (BMs) and from one healthy control biopsy using the 
RNeasy-kit (Qiagen, Chatsworth, CA) according to the manufacturer’s instructions. We verified 
high-quality of isolated RNA and RNA integrity using an Agilent Technologies 2100 
Bioanalyzer. The isolated RNA had RNA Integrity Number (RIN) value greater than 8. 
RNAseq  
1 g of total RNA sample was used for polyA+ mRNA selection using streptavidin-coated mag-
netic beads, followed by thermal mRNA fragmentation. Fragmented mRNA was retro-
transcribed using reverse transcriptase (Super-Script II) and random primers. The cDNA was 
converted into double stranded cDNA, its ends were repaired using Klenow fragment, T4 poly-
nucleotide kinase and T4 polymerase, and then cDNA was ligated to Illumina paired end (PE) 
adaptors. Size selection was performed using a 2% agarose gel, generating cDNA libraries rang-
ing in size from 200 to 250 bp. Finally, the libraries were enriched using 15 cycles of PCR (30 
seconds at 98° C; 15 cycles of 10 s at 98°C, 30 s at 65°C, and 30 s at 72°C; then 5 minutes at 
  
72°C) and purified by the QIAquick PCR purification kit (Qiagen). The enriched libraries were 
diluted with Elution Buffer to a final concentration of 10 nM. Each library was run at a concen-
tration of 7 pM on one Genome Analyzer (GAIIe) lane using paired-end 100 bp sequencing. 
We performed mapping of reads to human genome using TopHat software. TopHat, the splice 
junction mapper for RNA-Seq reads, was run with default parameters. Supplied annotations from 
hg19 Refseq refGene were downloaded from the UCSC Genome Browser. The mapping results 
from TopHat were then passed to Cuffdiff, a tool which finds significant changes in transcript 
expression. In Cuffdiff quartile normalization was turned on, Bias Correction was set on, Min 
Alignment Count was set to 10, and all other parameters were set to default. Both TopHat and 
Cuffdiff were run on the free pubic Galaxy server (http://galaxyproject.org/). To identify consist-
ently deregulated genes, differential probes were identified by OK test in Cufflinks (Trapnell et 
al., 2010). Log-ratios were calculated as difference between patient and control. 
 
Quantification of CLOCK and MAT2A transcripts by real-time PCR 
To validate the deregulated expression of CLOCK and MAT2A genes, we enlarged our patient 
cohort. We analysed twelve UCMD, nine BM, three patients with intermediate phenotypes and a 
pool made of muscle controls. All ColVI patients have been clinically characterized with regard 
to “circadian involvement” - date and time of biopsy, if the patients were fasting or taking drugs, 
if the patients were ambulatory and the presence of ventilation at the time of biopsy (Table S3). 
Total RNA was isolated from muscle sections using RNeasy Kit (QIAGEN, Chatsworth, CA) 
and reverse transcribed by using High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). In order to quantify the steady state level of CLOCK and MAT2A transcripts, 
commercially available TaqMan expression assays (Applied Biosystems) were used (CLOCK: 
Hs00231857_m1 NM_001267843 exon boundary 19-20; MAT2A: Hs01553622_g1 
NM_005911 exon boundary 5-6) as for -actin as housekeeping reference gene (ACTB Endoge-
nous Control). Real-time PCR was performed in triplicate on the Applied Biosystems Prism 
7900HT system, using 10 ng of cDNA and default parameters. Evaluation of transcripts levels 
was performed by the comparative CT method ( CT Method). Statistical analysis were per-
formed with Student’s t-test. 
 
Western blotting analysis in Col6a1-/- mice and ColVI patients  
For immunoblotting analysis, frozen muscle tissues from both patients and mice were ground in 
a dry ice-cooled mortar and stored at -80°C. An aliquot of each frozen muscle was suspended in 
lysis buffer (urea 7M, thiourea 2M, CHAPS 4%, Tris 30mM, and PMSF 1mM) and solubilized 
by sonication on ice. Samples were pooled and protein concentrations were determined using 
  
PlusOne 2D-Quant kit (GE Healthcare, Milan, Italy). Total protein extracts (50µg) from pooled 
Col6a1-/- (5 mice) and wt (5 mice) animal models, and from pooled UCMD (4 patients), BM (8 
patients), 30 unrelated patients with Duchenne (DMD) or Becker (BMD) muscular dystrophies, 
and healthy control (5 subjects) muscles, were loaded in triplicate and resolved on 14-8% gradi-
ent polyacrylamide gels. Blots were incubated with rabbit polyclonal primary antibodies as fol-
lows: anti-MAT2A (Novus Biologicals, NB110-94158, 1:1000), anti-CLOCK (Santa Cruz Bio-
technology, sc-25361, 1:500).  After washing, the membranes were incubated with anti-rabbit 
(GE Healthcare) secondary antibody conjugated with horseradish peroxidase (1:5000). The sig-
nals were visualized by chemiluminescence using the ECL Prime (GE Healthcare) detection kit 
and the Image Quant LAS 4000 (GE Healthcare) analysis system. Statistical analysis was per-
formed applying the ANOVA and Tukey tests (n=3, p<0.05). 
Manipulations of animals, required for the experiments described, are conform to the rules of the 
Animal Experimental Commission of the "Complesso Interdipartimentale A. Vallisneri, Univer-
sity of Padua (Italy)", where the work has been carried out. These regulations represent the ap-
plication of the D.L. 27/1/92 n. 116 of the Italian Government, which meets Directive 
86/609/EEC of the EU Council concerning the protection of animals used for experiments and 
scientific purposes. The presented procedures have been approved by the Animal Experimental 
Commission with the certificate n. 22675. 
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Figure legend 
Fig. 1. Differentially GO groups expressed in sample from pooled tissues from three muscle tis-
sues, diaphragm, gastrocnemius and tibialis anterior, of four Col6a1-/- and WT mice. Representa-
tion of the 334 genes differentially expressed in the "pooled" data from all three muscle groups 
(diaphragm, gastrocnemius and TA) of Col6a1-/- mice compared with “pooled” wild-type mus-
cles. 
Fig. 2. Regulators identified by SNEA upstream genes differentially expressed between Col6a1-/- 
and wild-type mice muscle tissues (p-value <0.05). Blue highlighting represents regulators 
whose targets are enriched by genes differentially expressed in samples “pooled” from three 
muscle types, diaphragm, gastrocnemius and tibialis anterior, of four Col6a1-/- in respect to WT 
mice yellow highlighting indicates regulators whose targets are enriched with differentially ex-
pressed genes that have the same direction of change in all muscle types; green highlighting rep-
resents regulators whose targets are enriched with differentially expressed genes with the same 
direction of change using both “pooled” and individual muscle approaches. 
Fig. 3. Circadian genes’ transcription and expression analysis on mice and human muscles. (A) 
Western blotting of CLOCK and MAT2A in three different muscle tissues (diaphragm, gas-
trocnemius and TA) of five, male 6 months aging, Col6a1-/- and wild-type mice revealed a sig-
nificant upregulation (t-test, P value<0,05) of Clock protein levels in the diaphragm and TA, 
whereas the MAT2a protein level was significant altered in TA and gastrocnemius, which 
showed an increase and decrease, respectively. (B) Immunoblotting to evaluate the protein levels 
of p62, 3(VI), 6(VI), 1(VI), Beclin 1, LC3, AMPK-P, AMPK and -tubulin in the gas-
trocnemius muscle of four, male 30–35 week old, wild-type and Bmal1-/- mice. The analysis 
identified a downregulation of 6(VI), and upregulation of 3(VI). Components of autophagic 
pathway were also affected, expressed as an increase in LC3 and decrease in p62. (C) Real-time 
analysis of of CLOCK gene (black bars) and MAT2A gene (white bars) transcription in the co-
hort of 12 BM and 12 UCMD patients. The analysis identified a significant deregulation of the 
CLOCK gene in the UCMD patients only (t-test, P value<0,0001). (D) Western blotting of 
CLOCK and MAT2A in four BM, eight UCMD patients, and 30 patients affected by other dis-
eases (BMD and DMD), as well as five healthy controls, showed a significant increase (ANO-
VA, P value <0.05) in Clock protein levels in UCMD patients only; MAT2A was slightly but 
significantly increased in BM patients. All the above described experiments were performed in 
triplicate. 
Fig. 4. Gene ontology groups in ColVI patients RNAseq output. (A) Representation of the dif-
ferentially expressed GO genes in the ColVI patients (UCMD, BMs, BM) compared to control. 
(B) Venn diagrams showing the number of genes, identified by RNAseq analysis, constantly de-
  
regulated in the ColVI patients. The patients shared an upregulation of genes involved in 
postsynaptic membrane, cell junction and synapse pathways, and a downregulation of genes be-
longing to response to DNA damage stimuli and DNA repair pathways. 
Fig. 5. Interactome pathway linking ColVI and circadian rhythms. This model is based on the lit-
erature data analyzed by Pathway Studio, and shows the connections between autophagy and cir-
cadian pathways. In this model the proposed pathophysiological mechanism of UCMD is that 
mTOR kinase activation due to ColVI deficiency yields not only downregulation of autophagy 
but also activation of HIF1A transcription factor, which in turn represses the expression of au-
tophagy components via FoxO3 inhibition. In addition, HIF1A physically interacts with several 
major components of the circadian rhythm pathway, bringing about a reduction of MYOD lev-
els. AKT1 directly inhibits GSK3-beta by phosphorylation. GSK3-beta is a central negative reg-
ulator of circadian rhythm that phosphorylates its components. GSK3-beta repression by AKT1 
further de-represses HIF1A, which is under GSK3-beta negative control.  
Fig. 6. Proposed models (A and B) that potentially link collagen VI myopathy and circadian 
genes:   
Mechanism A: Circadian rhythm deregulation is a downstream effect of collagen VI deficiency 
and contribute to muscle damage pathogenesis. The inappropriate persistence of AKT1 activa-
tion could follow reduced ColVI expression, leading not only to the downregulation of autopha-
gy (also related to mTOR overexpression) but also to the activation of HIF1A transcription fac-
tor and the downregulation of GSK3-beta kinase. HIF1A physically interacts with several central 
components of the circadian rhythm pathway: BMAL1/ARNTL/MOP3 protein (Hogenesch et 
al., 1998), PER1 (Chilov et al., 2001), PER2 (Koyanagi et al., 2003) and ROR-alpha. HIF1A ac-
tivation has been shown to increase levels of PER1 and CLOCK proteins (Chilov et al., 2001). 
The increased levels of PER1, the negative regulator of circadian rhythm, may lead to decreased 
transcriptional activity of BMAL1-CLOCK heterodimer, thereby slowing down circadian oscil-
lations.  GSK3-beta also plays a role in the post-translational regulation of molecular clock com-
ponents, targetting BMAL1 for degradation at the end of the circadian cycle and stabilizing Rev-
ErbA, a negative regulator of BMAL1 transcription (Pritchett et al., 2012). 
Mechanism B: Circadian rhythm deregulation in collagen VI myopathies is an independent event 
acting as a secondary modifier of disease severity. The collagen VI 6 chain is downregulated in 
the mouse circadian model, suggesting that circadian genes can influence the primary COLVI 
defect, as supported by the direct control circadian genes have on MyoD (muscle development) 
and ATG14 (autophagy circuit) proteins. Downregulation of CLOCK induces ATG14 persis-
tence and autophagy activation, whereas MyoD overexpression alters regeneration and induces 
muscle damage). 
  
Table 1: List of the seven upregulated and 24 downregulated genes, identified by RNAseq, con-
sistently represented in all three patients. 
  
Table 1 
GENE NAME UP/DOWN 
REGULATED ACCESSION NUM-BER OMIM FUCTION CORRELATION WITH NEUROMUS-
CULAR DISEASE 
FOLD-CHANGE 
BM BMs UCMD 
ZNF384 Zinc Finger 
Protein 384 Up NM_001039919 *609951 Transcription factor that regulate the promoters of the extracellular matrix 
genes MMP1, MMP3, MMP7 and 
COL1A1 
 39,3095 37,233 39,7226 
ZNF526 Zinc Finger 
Protein 526 Up NM_133444 *614387 Transcription factor  2,7601 1,6734 1,6813 
SCP2 Sterol Carrier 
Protein 2 Up NM_001007250 *184755 SCP2 protein is involved in the lipid me-tabolism leukoencephalopathy with dystonia and motor 
neuropathy 
2,0683 2,2456 1,4437 
SUOX Sulfite Oxidase Up NM_000456 *606887 The SUOX enzyme catalyzes the oxidation 
of sulfite to sulfate Sulfite oxidase deficien-cy 37,8363 38,1009 39,0129 
KIF1B Kinesin Family 
Member 1B Up NM_015074 *605995 This gene encodes a motor protein that transports mitochondria and synaptic ves-
icle precursors. 
Charcot-Marie-Tooth 
disease, type 2A1 3,1132 2,5426 1,9332 
PCSK6 Proprotein 
Convertase 
Subtili-
sin/Kexin Type 
6 
Up NM_138321 *167405 PCSK6 encoded protein is a calcium-
dependent serine endoprotease that can 
cleave precursor protein at their paired 
basic amino acid processing sites. Some of 
its substrates are - transforming growth 
factor beta related proteins, proalbumin, 
and von Willebrand factor. 
 1,7039 2,2606 1,9061 
SESN1 Sestrin 1 Up NM_014454 *606103 SESN1 play a role in the cellular response 
to DNA damage and oxidative stress  1,8542 1,5004 1,4777 
  
CRY2 Cryptochrome 
Circadian 
Clock 2 
Down NM_021117 *603732 Circadian gene necessary for the genera-
tion of circadian rhythms  -40,4144 -1,1962 -40,3619 
MAT2A Methionine 
Adenosyltransf
erase II, Alpha 
Down NM_005911 *601468 MAT2A catalyzes the production of S-
adenosylmethionine (AdoMet) from me-
thionine and 
ATP 
 -2,7992 -2,2145 -3,7638 
ARTN Artemin Down NM_001136215 *603886 ARTN is involved in signaling of dopa-
minergic CNS neurons  -1,9588 -3,0809 -4,4802 
WNT3A Wingless-Type 
MMTV Inte-
gration Site 
Family, Mem-
ber 3A 
Down NM_033131 *606359 Ligand for members of the frizzled family 
of seven transmembrane receptors. Wnt3a 
play roles in cell-cell signaling 
 -1,7748 -1,5573 -1,6244 
PTPN11 Protein Tyro-
sine Phospha-
tase, Non-
Receptor Type 
11 
Down NM_002834 *176876 Protein tyrosine phosphatases (PTPs) are 
a group of enzymes that catalyze the re-
moval of phosphate groups 
from tyrosine residues by the hydrolysis of 
phosphoric acid monoesters. PTPN11 par-
ticipates in the 
signal transduction from the cell surface 
to the nucleus 
 -1,8989 -3,1835 -1,9862 
  
CD3G CD3g 
Molecule, 
Gamma (CD3-
TCR Complex) 
Down NM_000073 *186740 The protein encoded by this gene is the 
CD3-gamma polypeptide, which together 
with CD3-epsilon, -delta and -zeta, 
and the T-cell receptor alpha/beta and 
gamma/delta heterodimers, forms the T-
cell receptor-CD3 complex. This 
complex plays an important role in cou-
pling antigen recognition to several intra-
cellular signal-transduction 
pathways 
 -38,1546 -37,7322 -3,2284 
CDH1 Cadherin 1, 
Type 1, E-
Cadherin 
(Epithelial) 
Down NM_004360 *192090 CDH1 is a calcium dependent 
cell-cell adhesion glycoprotein  -1,6719 -2,049 -1,3894 
DMAP1 DNA 
Methyltransfer
ase 1 Associat-
ed Protein 1 
Down NM_001034024 *605077 DMAP1 is involved in transcription re-
pression and activation.  -37,8224 -37,4289 -37,7671 
ZNF181 Zinc finger 181 Down NM_001145665 *606741 May be involved in transcriptional regula-
tion  -1,4527 -1,0334 -1,6816 
ZNF233 Zinc finger 233 Down NM_181756 - May be involved in transcriptional regula-
tion  -1,7889 -0,9786 -1,4194 
ZNF619 Zinc finger 619 Down NM_001145083 - May be involved in transcriptional regula-
tion  -3,487 -1,1514 -1,6887 
  
GCKR Glucokinase 
(Hexokinase 4) 
Regulator 
Down NM_001486 *600842 GCKR is a regulatory protein that inhib-
its glucokinase in liver and pancreatic islet 
cells by binding 
non-covalently to form an inactive com-
plex with the enzyme. 
 -2,2272 -1,2255 -2,0378 
PGLS 6-
phosphoglucon
olactonase 
Down NM_012088 *604951 Hydrolysis of 6-phosphogluconolactone to 
6-phosphogluconate  -2,4972 -2,65 -2,341 
SCO1 SCO1 Cyto-
chrome C Oxi-
dase Assembly 
Protein 
Down NM_004589 *603644 Thought to play a role in cellular copper 
homeostasis, mitochondrial redox signal-
ing or insertion of 
copper into the active site of COX 
 -1,7047 -1,5227 -2,4417 
GPR15 G Protein-
Coupled Re-
ceptor 15 
Down NM_005290 *601166 This gene encodes a G protein-coupled 
receptor that acts as a chemokine receptor 
for human immunodeficiency virus 
type 1 and 2. 
 -2,1248 -1,7917 -1,7865 
ITPRIP Inositol 1,4,5-
Trisphosphate 
Receptor In-
teracting Pro-
tein 
Down NM_033397 - ITPRIP encodes a membrane-associated 
protein that binds the inositol 1,4,5-
trisphosphate receptor (ITPR). The 
encoded protein enhances the sensitivity 
of ITPR to intracellular calcium signaling. 
 -4,7234 -5,8684 -4,4783 
ADCY4 Adenylate 
Cyclase 4 Down NM_001198568 *600292 ADCY4 is membrane-associated enzymes that catalyze the formation of the second-
ary messenger cyclic adenosine mono-
phosphate (cAMP) 
 -3,4624 -2,0732 -2,4598 
  
NEDD1 Neural Precur-
sor Cell Ex-
pressed Devel-
opmentally 
Down-
Regulated Pro-
tein 1 
Down NM_001135177 *600372 NEDD1 is required for mitosis progres-
sion. Promotes the nucleation of microtu-
bules from the spindle 
 -40,2291 -39,7942 -40,1467 
HECTD3 HECT Domain 
Containing E3 
Ubiquitin Pro-
tein Ligase 3 
Down NM_024602 - HECTD3 mediates ubiquitination of 
TRIOBP and 
its subsequent proteasomal degradation, 
thus faciliting cell cycle progression by 
regulating the turn-over of TRIOBP. Me-
diates also ubiquitination of STX8 
 -1,7798 -1,0458 -1,6116 
ERP27 Endoplasmic 
Reticulum Pro-
tein 27 
Down NM_152321 *610642 ERP27 is a noncatalytic member of the 
protein disulfide isomerase family of en-
doplasmic 
reticulum (ER) proteins 
ataxia -5,3233 -2,0534 -2,0794 
MID1IP1 MID1 Interact-
ing Protein 1 Down NM_021242 - MID1IP1 plays a role in the regulation of lipogenesis in liver.  -2,015 -1,4034 -1,8172 
C1orf64 Chromosome 1 
Open Reading 
Frame 64 
Down NM_178840 - Involved breast and colorectal cancer  -38,3313 -3,1196 -38,2086 
TMEM110 Transmembran
e Protein 110 Down NM_198563 - Structural protein  -1,6315 -1,1639 -1,1536 
PRSS42 Protease, Ser-
ine, 42 Down NM_182702 - serine-type endopeptidase activity  -2,0183 -1,6536 -1,726 
 






